Summary’
Exscientia plc, a leader in artificial intelligence-driven drug discovery, is poised to present significant new preclinical findings concerning its LSD1 and MALT1 inhibitors at the upcoming 36th EORTC-NCI-AACR (ENA) Symposium 2024, scheduled for October 23-25 in Barcelona, Spain. These developments mark a significant step forward in Exscientia’s commitment to advancing innovative therapies for oncology, a field in which precision medicine has become critically important.
The ongoing evolution of drug discovery technologies has invigorated the pharmaceutical industry, particularly in the domain of precision medicine. Exscientia is at the forefront of this innovation, employing artificial intelligence (AI) for the design and optimization of small molecule inhibitors. The company’s focus on LSD1 (lysine-specific demethylase 1) and MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1) inhibitors is particularly noteworthy, as these targets have emerged as critical components in the pathogenesis of various malignancies.
The Role of LSD1 and MALT1 in Cancer’
LSD1 plays a vital role in epigenetic regulation and is implicated in various cancers, including acute myeloid leukemia and solid tumors. By demethylating lysine residues on histones, LSD1 contributes to the transcriptional activation of oncogenes and repressive effects on tumor suppressor genes.
MALT1, a key player in NF-κB signaling, has been linked to multiple lymphoid malignancies. Targeting the MALT1 signaling pathway presents a novel approach to disrupt cellular proliferation and survival in these malignancies.
Presentation Highlights at ENA 2024’
At the ENA 2024 Symposium, Exscientia’s team will present three abstracts detailing new preclinical findings obtained through AI-driven discovery platforms. Dr. David Hallett, interim CEO and Chief Scientific Officer of Exscientia, is enthusiastic about sharing these insights, stating, “As our precision-designed LSD1 and MALT1 inhibitors continue to progress towards the clinic, we are excited to share new preclinical data from both programmes.”
The presentations will encompass data on:
’Mechanism of Action’: Insights into how the AI-designed inhibitors interact at the molecular level with their respective targets, thereby perturbing oncogenic pathways.
’Efficacy Studies’: Data demonstrating the potency and selectivity of these inhibitors in preclinical cancer models, supporting their potential as therapeutic agents.
’Pharmacokinetic Profiles’: Information on the metabolic stability and bioavailability of the SLD1 and MALT1 inhibitors, critical elements for advancing into clinical trials.
The combination of these findings contributes significantly to understanding the therapeutic window for these inhibitors, potentially leading to innovative treatment options for patients suffering from resistant forms of cancer.
Conclusion’
Exscientia’s upcoming presentations at the ENA 2024 highlight the convergence of AI technology with drug discovery, particularly in the pursuit of targeted therapies for cancer. As the company moves closer to clinical application of its findings, the implications for treatment paradigms in oncology are substantial. This emphasis on precision inhibitors underscores the importance of collaboration between technology and science in achieving breakthroughs in pharmaceutical development.
As the field of drug discovery continues to evolve, the contributions from companies like Exscientia will be essential in shaping the future of precision medicine, offering hope for improved outcomes for cancer patients worldwide.Title’: Exscientia to Present New Preclinical Data on AI-Designed LSD1 and MALT1 Inhibitors at ENA 2024, Advancing Precision Medicine in Oncology
Comments